Bloodwise   Report issue

Foundation Phase 2
Founded: London United Kingdom (1960)

Organization Overview

First Clinical Trial
2014
NCT02424851
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Bloodwise

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 14